Pictet Asset Management Holding SA trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 14.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,072,802 shares of the biotechnology company’s stock after selling 176,969 shares during the quarter. Pictet Asset Management Holding SA’s holdings in BioCryst Pharmaceuticals were worth $8,874,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nykredit A S purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $27,000. IFP Advisors Inc grew its position in BioCryst Pharmaceuticals by 2,515.3% during the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 3,119 shares during the last quarter. Allworth Financial LP purchased a new position in BioCryst Pharmaceuticals during the 2nd quarter worth $52,000. Hilltop Holdings Inc. purchased a new position in BioCryst Pharmaceuticals during the 1st quarter worth $98,000. Finally, Sterling Capital Management LLC increased its stake in BioCryst Pharmaceuticals by 1,373.8% in the third quarter. Sterling Capital Management LLC now owns 12,056 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 11,238 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 8th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. JPMorgan Chase & Co. increased their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $13.00 to $11.00 in a research report on Thursday, September 10th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.38.
Get Our Latest Report on BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Price Performance
Shares of BCRX stock opened at $7.61 on Monday. The business’s fifty day moving average price is $8.23 and its 200 day moving average price is $8.78. The firm has a market capitalization of $1.96 billion, a PE ratio of -5.36 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.23 and a 1-year high of $11.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative net margin of 37.40% and a negative return on equity of 92.91%. The company had revenue of $180.29 million for the quarter, compared to analyst estimates of $165.67 million. During the same period in the previous year, the firm earned $0.06 EPS. The business’s revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.28 earnings per share for the current fiscal year.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.
Read More
- Five stocks we like better than BioCryst Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
